Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 8.413
Filtrer
1.
Medicina (Kaunas) ; 60(6)2024 Jun 01.
Article de Anglais | MEDLINE | ID: mdl-38929539

RÉSUMÉ

Background and Objectives: Human papillomavirus (HPV) infection and its etiological role in the development of cervical cancer are well established. The cervical cancer mortality rate in Serbia is one of the highest among European countries, and this cancer is the second-leading cause of death in Serbian women aged from 15 to 44. Materials and Methods: This retrospective study was conducted at the Institute of Public Health of Vojvodina. A total of 10,062 cervical specimens from Serbian women were collected and HPV tested in ten years. The study patients were divided into five age groups. HPV genotype testing was performed using a commercial kit to detect 14 high-risk (HR) HPV genotypes. Additionally, cervix cytology data have been available for patients tested in 2022 and 2023. Results: An overall positive rate was found in 43.3% of patients (4356/10,062). A single HPV infection (62.1%) was the main infection pattern. The most frequent HR HPV genotypes were HPV 16, 31, 52, 56, 39, and 51, comprising 62.3% of the detected genotypes, including multiple infections. A significant difference was noted in the HPV prevalence across the different age groups, with a bimodal distribution of HPV infection. The highest prevalence was recorded in the age group ≤ 30 and those after 61 years. Women diagnosed with high-grade squamous intraepithelial lesions (HSIL) were significantly older compared to others. HR HPV is the most prevalent in patients with HSIL cytological findings (76.5%). The most common type, according to age-specific distribution and cytological findings, was HR HPV 16. Conclusions: This study provides comprehensive data on HR HPV distribution among Serbian women, which can serve as a basis for subsequent monitoring of genotypic distribution. It is particularly significant considering they are missing in the updated ICO/IARC Report for Serbia, and the cervical cancer mortality rate in Serbia is one of the highest among European countries.


Sujet(s)
Génotype , Papillomaviridae , Infections à papillomavirus , Tumeurs du col de l'utérus , Humains , Femelle , Serbie/épidémiologie , Infections à papillomavirus/épidémiologie , Infections à papillomavirus/virologie , Adulte , Études rétrospectives , Prévalence , Adulte d'âge moyen , Adolescent , Papillomaviridae/génétique , Tumeurs du col de l'utérus/virologie , Tumeurs du col de l'utérus/épidémiologie , Jeune adulte , Sujet âgé
2.
PLoS One ; 19(6): e0306044, 2024.
Article de Anglais | MEDLINE | ID: mdl-38917143

RÉSUMÉ

BACKGROUND: Danish women-who were HPV-vaccinated as girls-are now reaching an age where they are invited to cervical cancer screening. Because of their expected lower cervical cancer risk, we must reassess our screening strategies. We analyzed Danish HPV-vaccinated women's outcomes after the first screening test at age 23. METHODS AND FINDINGS: Our study was embedded in Danish routine cytology-based screening. We conducted an observational study and included women born in 1994, offered the 4-valent HPV vaccine at age 14, and subsequently invited to screening at age 23. Cervical cytology was used for diagnostics and clinical management. Residual material was HPV tested with Cobas® 4800/6800. The most severe histology diagnosis within 795 days of screening was found through linkage with the Danish National Pathology Register. We calculated the number of women undergoing follow-up (repeated testing and/or colposcopy) per detected cervical intraepithelial neoplasia (CIN2+). A total of 6021 women were screened; 92% were HPV-vaccinated; 12% had abnormal cytology; 35% were high-risk HPV-positive, including 0.9% HPV16/18 positive, and 20% had follow-up. In women that were cytology-abnormal and HPV-positive (Cyt+/HPV+), 610 (98.5%) had been followed up, and 138 CIN2+ cases were diagnosed, resulting in 4.4 (95% CI 3.9-5.2) women undergoing follow-up per detected CIN2+. In contrast to recommendations, 182 (12.2%) cytology-normal and HPV-positive (Cyt-/HPV+) women were followed up within 795 days, and 8 CIN2+ cases were found, resulting in 22.8 (95% CI 13.3-59.3) women undergoing follow-up per detected CIN2+. CONCLUSION: Overall, HPV prevalence was high in HPV-vaccinated women, but HPV16/18 had largely disappeared. In the large group of cytology-normal and HPV-positive women, 23 had been followed up per detected CIN2+ case. Our data indicated that primary HPV screening of young HPV-vaccinated women would require very effective triage methods to avoid an excessive follow-up burden. TRIAL REGISTRATION: Trial registration number: NCT0304955.


Sujet(s)
Dépistage précoce du cancer , Infections à papillomavirus , Vaccins contre les papillomavirus , Tumeurs du col de l'utérus , Humains , Femelle , Danemark/épidémiologie , Vaccins contre les papillomavirus/administration et posologie , Tumeurs du col de l'utérus/virologie , Tumeurs du col de l'utérus/diagnostic , Tumeurs du col de l'utérus/épidémiologie , Tumeurs du col de l'utérus/prévention et contrôle , Infections à papillomavirus/diagnostic , Infections à papillomavirus/épidémiologie , Infections à papillomavirus/virologie , Infections à papillomavirus/prévention et contrôle , Dépistage précoce du cancer/méthodes , Jeune adulte , Études de cohortes , Dysplasie du col utérin/diagnostic , Dysplasie du col utérin/virologie , Dysplasie du col utérin/épidémiologie , Dysplasie du col utérin/prévention et contrôle , Adulte , Adolescent , Vaccination , Papillomavirus humain de type 18/isolement et purification , Dépistage de masse/méthodes
3.
PLoS One ; 19(6): e0304760, 2024.
Article de Anglais | MEDLINE | ID: mdl-38870122

RÉSUMÉ

PURPOSE: The genotype distribution of human papillomavirus (HPV) infection varies greatly in different regions. This study aims to determine the prevalence and type-specific distribution of HPV among females from Chengdu and Aba in Sichuan Province, which differ in geographical location, economic status, and living habits. These can serve as evidence of epidemic patterns for future design and implementation of vaccination and screening programs. METHODS: A retrospective cross-sectional study was conducted on 144 113 women who underwent cervical screening at Chengdu Women's and Children's Central Hospital from January 2015 to September 2020. Meanwhile, 1799 samples from February 2018 to December 2021 were collected from Aba Maternal and Child Health Hospital. HPV DNA genotype testing was performed using real-time PCR. The overall prevalence, annual trend, age-specific prevalence, and type distribution were analyzed. RESULTS: The overall HPV prevalence was 22.51% in Chengdu. During 2015-2020, the highest prevalence rate was observed in 2018. Age-specific HPV distribution displayed a bimodal distribution among women aged ≤25 or ≥46 years old. The top three prevalent genotypes were HPV52, -16, and -58. Although the total prevalence of HPV in Aba was 14.23%, there was an upward trend from 2018 to 2021. However, no significant differences were identified in HPV infection rate across all age groups. HPV52, -53, and -16 were the major genotypes. Furthermore, single-type HPV infections and high-risk HPV infections were identified as the most common infection types in both regions. CONCLUSION: Our findings demonstrate the overall prevalence of HPV was still high in Chengdu and Aba. The age-specific prevalence distribution demonstrated different patterns. Non-vaccine-covered HR-HPV53, -51and LR-HPV81, -CP8304 were frequently detected, which was worth significant clinical attention. In summary, regional HPV screening provides valuable clinical guidance for cervical cancer prevention and vaccine selection in Western China.


Sujet(s)
Papillomaviridae , Infections à papillomavirus , Humains , Femelle , Chine/épidémiologie , Infections à papillomavirus/épidémiologie , Infections à papillomavirus/virologie , Adulte , Prévalence , Adulte d'âge moyen , Études transversales , Études rétrospectives , Papillomaviridae/génétique , Papillomaviridae/classification , Papillomaviridae/isolement et purification , Jeune adulte , Génotype , Tumeurs du col de l'utérus/épidémiologie , Tumeurs du col de l'utérus/virologie , ADN viral/génétique , Col de l'utérus/virologie
4.
Front Public Health ; 12: 1357311, 2024.
Article de Anglais | MEDLINE | ID: mdl-38873306

RÉSUMÉ

Limited data exist on HPV prevalence and genotyping during the COVID-19 pandemic. A total of 130,243 samples from 129, 652 women and 591 men who visited the First People's Hospital of Linping District between 2016 and 2022 were recruited. HPV genotypes were detected by polymerase chain reaction (PCR) amplification and nucleic acid molecular hybridization. Then the prevalence characteristics of HPV genotypes and trends in HPV infection rates from 2016 to 2022 were analyzed. Results showed that among the study population, the overall prevalence of HPV infection was 15.29%, with 11.25% having single HPV infections and 4.04% having multiple HPV infections, consistent with previous findings. HPV genotypes exhibited similar distribution patterns in both male and female groups, with HPV16, HPV52, HPV58, HPV18, and HPV39 being the most prevalent. Age-related analysis unveiled a bimodal pattern in HPV prevalence, with peaks in infection rates observed in individuals below 20 and those aged 61-65 years. Comparing the pre- and during COVID-19 periods revealed significant disparities in HPV infections, with variations in specific HPV genotypes, including 16, 18, 35, 45, 52, 58, 59, and 68. This study provides valuable insights into the prevalence, distribution, and epidemiological characteristics of HPV infections in a large population. It also highlights the potential impact of the COVID-19 pandemic on HPV trends.


Sujet(s)
COVID-19 , Génotype , Papillomaviridae , Infections à papillomavirus , Humains , COVID-19/épidémiologie , COVID-19/virologie , Infections à papillomavirus/épidémiologie , Infections à papillomavirus/virologie , Femelle , Chine/épidémiologie , Mâle , Prévalence , Adulte d'âge moyen , Adulte , Sujet âgé , Papillomaviridae/génétique , Papillomaviridae/isolement et purification , Jeune adulte , SARS-CoV-2/génétique , Adolescent , Pandémies/statistiques et données numériques
5.
BMJ Open ; 14(6): e080395, 2024 Jun 10.
Article de Anglais | MEDLINE | ID: mdl-38858160

RÉSUMÉ

INTRODUCTION: Multiplathogen home-based self-sampling offers an opportunity to increase access to screening and treatment in endemic settings with high coinfection prevalence of sexually transmitted (HIV, Trichomonas vaginalis (Tv), human papillomavirus (HPV)) and non-sexually transmitted pathogens (Schistosoma haematobium (Sh)). Chronic coinfections may lead to disability (female genital schistosomiasis) and death (cervical cancer). The Zipime-Weka-Schista (Do self-testing sister!) study aims to evaluate the validity, acceptability, uptake, impact and cost-effectiveness of multipathogen self-sampling for genital infections among women in Zambia. METHODS AND ANALYSIS: This is a longitudinal cohort study aiming to enrol 2500 non-pregnant, sexually active and non-menstruating women aged 15-50 years from two districts in Zambia with 2-year follow-up. During home visits, community health workers offer HIV and Tv self-testing and cervicovaginal self-swabs for (1) HPV by GeneXpert and, (2) Sh DNA detection by conventional (PCR)and isothermal (recombinase polymerase assay) molecular methods. Schistosoma ova and circulating anodic antigen are detected in urine. At a clinic follow-up, midwives perform the same procedures and obtain hand-held colposcopic images. High-risk HPV positive women are referred for a two-quadrant cervical biopsy according to age and HIV status. A cost-effectiveness analysis is conducted in parallel. ETHICS AND DISSEMINATION: The University of Zambia Biomedical Research Ethics Committee (UNZABREC) (reference: 1858-2021), the London School of Hygiene and Tropical Medicine (reference: 25258), Ministry of Health and local superintendents approved the study in September 2021.Written informed consent was obtained from all participants prior to enrolment. Identifiable data collected are stored securely and their confidentiality is protected in accordance with the Data Protection Act 1998.


Sujet(s)
Analyse coût-bénéfice , Infections à VIH , Dépistage de masse , Infections à papillomavirus , Humains , Femelle , Zambie/épidémiologie , Études longitudinales , Adulte , Adolescent , Jeune adulte , Adulte d'âge moyen , Infections à papillomavirus/diagnostic , Infections à papillomavirus/épidémiologie , Infections à VIH/diagnostic , Infections à VIH/épidémiologie , Dépistage de masse/méthodes , Dépistage de masse/économie , Co-infection/diagnostic , Auto-dépistage , Animaux , Bilharziose urinaire/diagnostic , Bilharziose urinaire/épidémiologie , Vaginite à Trichomonas/diagnostic , Vaginite à Trichomonas/épidémiologie , Trichomonas vaginalis/isolement et purification , Tumeurs du col de l'utérus/diagnostic , Tumeurs du col de l'utérus/virologie , Virus des Papillomavirus humains
6.
PLoS One ; 19(6): e0302153, 2024.
Article de Anglais | MEDLINE | ID: mdl-38848414

RÉSUMÉ

INTRODUCTION: Cervical cancer, a malignancy caused by infection with oncogenic human papillomavirus, disproportionally affects women from low resource settings. Persistence of human papillomavirus infection may mediate an association between tobacco use and cervical cancer. In limited resource settings, women from indigenous communities are often marginalized and do not benefit from evidence-based interventions to prevent tobacco use or cervical cancer due to the limited reach of mainstream healthcare services to these communities. This study determined the association between smoking and high-risk human papillomavirus infection among women from indigenous communities in western Botswana. METHODS: A cross-sectional study of women in indigenous communities was conducted between June and October 2022. Demographic, clinical and self-reported smoking data were collected. Cervical cytology and HPV DNA testing for high-risk human papillomavirus genotypes were performed. Multilevel multivariable logistic regression models were fit to evaluate the association between smoking and high-risk human papillomavirus infection while adjusting for potential confounders. RESULTS: A total of 171 participants with a median (interquartile range) age of 40 (31-50) years from three settlements and two villages were recruited for the study. Of these, 17% were current smokers, 32.8% were living with HIV and high-risk human papillomavirus DNA was detected in 32.8% of the cervical specimens. Women who were current smokers, were nearly twice as likely to have cervical high-risk human papillomavirus infection compared to non-smokers (Adjusted Odds Ratio (95% CI); 1.74(1.09, 2.79)) after controlling for confounders. CONCLUSION: These data underscore the need for effective tobacco control to help mitigate cervical cancer risk in this setting. These findings can help inform decisions about targeted cervical cancer prevention and tobacco cessation interventions for women from indigenous communities.


Sujet(s)
Infections à papillomavirus , Fumer , Tumeurs du col de l'utérus , Humains , Femelle , Infections à papillomavirus/épidémiologie , Infections à papillomavirus/virologie , Botswana/épidémiologie , Adulte , Adulte d'âge moyen , Études transversales , Tumeurs du col de l'utérus/virologie , Tumeurs du col de l'utérus/épidémiologie , Tumeurs du col de l'utérus/étiologie , Tumeurs du col de l'utérus/prévention et contrôle , Peuples autochtones/statistiques et données numériques , Papillomaviridae/isolement et purification , Papillomaviridae/génétique , Facteurs de risque
7.
BMC Public Health ; 24(1): 1548, 2024 Jun 07.
Article de Anglais | MEDLINE | ID: mdl-38849788

RÉSUMÉ

BACKGROUND: Human Papillomavirus (HPV) infection is a significant public health concern globally, especially in low- and middle-income countries. In Africa, including Nigeria, HPV prevalence is high, contributing to a substantial burden of cervical cancer. Despite challenges, massive HPV vaccination campaigns in Africa show promise for preventing cervical cancer cases. In Benue State, Nigeria, limited research exists on several aspects of HPV knowledge and attitudes towards HPV among secondary school students. This study aims to bridge this gap by assessing HPV knowledge, prevention practices, willingness to uptake HPV vaccination, and associated attitudes and behaviors among secondary school students in the state. METHODS: The cross-sectional study was conducted among adolescents aged 10-19 years in six secondary schools in three local government areas (LGAs) in Benue State, Nigeria. Two-stage sampling was used to select the LGAs and schools, with a final sample size of 591 students. The selected schools represent both junior and senior secondary school levels and span across the three senatorial districts of the state. Data were collected using a self-administered questionnaire covering sociodemographic characteristics, HPV knowledge, prevention practices, and willingness for HPV vaccination. Statistical analyses included univariate analyses and tests of association, with significance set at p < 0.05 or 0.001 depending on the level of the stringency of the evidence required. Data were analyzed using SPSS version 25. RESULTS: Only 35.4% of the participants were males, and 86.8% were between the ages of 10 and 16. Only 24.7% acknowledged that HPV can be transmitted during sexual intercourse, and 36.2% recognized that HPV can be transmitted via skin-to-skin contact. 48.1% noted that HPV can cause cervical cancer. Half (50.9%) acknowledged that early sexual debut increases the risk of acquiring HPV, while only 28.1% recognized vaccination as a preventive strategy against HPV infection. Only 35% correctly stated the best time for the HPV vaccine. In assessing the practice of HPV prevention, 14.9% are in a sexual relationship and 10.3% admitted to not using condoms during sexual intercourse. Also, 11.8% have had STIs, and 27.2% have previously undergone HIV screening. Various bivariate analyses showed some varying behavioral differences and correlates of HPV infection among young adolescents in Benue State, Nigeria. CONCLUSIONS: This study provides valuable insights into HPV knowledge, prevention practices, and willingness to uptake HPV vaccination among secondary school students in Benue State, Nigeria. The significance of the differences and correlates was discussed using themes. The research has unpacked complex relationships that could have public health implications for researchers and policymakers. Moreover, ten actionable policy recommendations were prescribed. Several interventions and areas for further study were proposed.


Sujet(s)
Connaissances, attitudes et pratiques en santé , Infections à papillomavirus , Vaccins contre les papillomavirus , Humains , Nigeria/épidémiologie , Adolescent , Infections à papillomavirus/prévention et contrôle , Infections à papillomavirus/épidémiologie , Femelle , Études transversales , Mâle , Jeune adulte , Enfant , Vaccins contre les papillomavirus/administration et posologie , Enquêtes et questionnaires , Comportement de l'adolescent/psychologie , Étudiants/psychologie , Étudiants/statistiques et données numériques , Comportement sexuel/statistiques et données numériques , Comportement sexuel/psychologie
8.
PLoS One ; 19(6): e0305122, 2024.
Article de Anglais | MEDLINE | ID: mdl-38861542

RÉSUMÉ

BACKGROUND: Advances in laboratory techniques for HPV diagnosis necessitate a thorough assessment of the efficiency, replicability, sensitivity, and specificity of those methods. This study aims to validate and compare HPV detection/genotyping using the Anyplex™ II HPV28 Detection assay (Seegene) assay and the Linear Array HPV Genotyping test (Roche Diagnostics) on genital samples for use in epidemiological studies. METHODS: From 6,388 penile and cervical DNA samples collected in the POP-Brazil, 1,745 were randomly selected to be included in this study. The samples were submitted to HPV detection and genotyping following the manufacturers' protocols. DNA was genotyped using the Anyplex™ II HPV28 Detection kit (Seegene), and the results were compared to those obtained using the Linear Array HPV Genotyping test (Roche Diagnostics). Concordance of HPV genotyping results was assessed by the percentage agreement and Cohen's kappa score (κ). RESULTS: The agreement between the two methodologies was deemed good for HPV detection (κ = 0.78). Notably, Anyplex™ II HPV28 demonstrated enhanced capability in detecting a broader spectrum of genotypes compared to Linear Array. CONCLUSION: Anyplex™ II HPV28 exhibited comparable results to the Linear Array assay in clinical specimens, showcasing its potential suitability for a diverse array of research applications requiring the detection and genotyping of HPV. The study supports the utility of Anyplex™ II HPV28 as an effective tool for HPV screening in epidemiological studies, emphasizing its robust performance in comparison to established diagnostic tests.


Sujet(s)
Génotype , Techniques de génotypage , Papillomaviridae , Infections à papillomavirus , Humains , Brésil/épidémiologie , Infections à papillomavirus/diagnostic , Infections à papillomavirus/virologie , Infections à papillomavirus/épidémiologie , Femelle , Techniques de génotypage/méthodes , Mâle , Papillomaviridae/génétique , Papillomaviridae/classification , Papillomaviridae/isolement et purification , ADN viral/génétique , Adulte , Adulte d'âge moyen , Sensibilité et spécificité , Alphapapillomavirus
9.
PLoS One ; 19(6): e0304147, 2024.
Article de Anglais | MEDLINE | ID: mdl-38861564

RÉSUMÉ

BACKGROUND: Colorectal cancer (CRC) is a cancer type that is thought to be influenced by human papillomaviruses (HPVs) and human polyomaviruses (HPyVs). In Egypt, CRC ranks as the 7th most common cancer, accounting for 3.47% of male cancers and 3% of female cancers. However, there is currently a lack of information regarding the presence of PyVs and HPVs co-infection specifically in CRC cases in Egypt. Therefore, the aim of this study was to investigate the occurrence of HPVs and HPyVs (JCPyV, BKPyV, and SV40) infections, as well as co-infections, among CRC patients in Egypt. Additionally, the study aimed to assess any potential association between these viral infections and tumor stages. METHODS: In the present study, we analyzed a total of 51 tissue samples obtained from Egyptian CRC patients, along with 19 polyps' samples. Our investigation focused on the detection and genotyping of HPyVs using Real-Time PCR. Additionally, we employed real-time PCR for the detection of HPVs, and for their genotyping, we utilized a combination of PCR amplification followed by sequencing. RESULTS: In our study, we found evidence of HPyVs infection in the CRC patients, specifically SV40 (25.5%) and BKPyV (19.6%). However, JCPyV was not detected in the samples that were examined. Additionally, we discovered that HPV was present in 43.1% of the CRC patients. When considering viral co-infections, 19.6% of the CRC samples showed coexistence of multiple viruses, while no co-infections were found in the polyps samples. Importantly, we observed a significant correlation between the presence of HPVs and advanced colorectal tumor grades B2 and D. CONCLUSION: Our findings provide valuable data for the detection of oncogenic viruses in colorectal cancer (CRC) and underscore the association of viral co-infections with advanced tumor stages. However, further research with larger cohorts is necessary to validate these findings and strengthen their significance in the field of CRC.


Sujet(s)
Tumeurs colorectales , Papillomaviridae , Infections à papillomavirus , Infections à polyomavirus , Polyomavirus , Humains , Tumeurs colorectales/virologie , Égypte/épidémiologie , Femelle , Mâle , Adulte d'âge moyen , Infections à polyomavirus/virologie , Infections à polyomavirus/épidémiologie , Infections à polyomavirus/complications , Infections à papillomavirus/virologie , Infections à papillomavirus/épidémiologie , Infections à papillomavirus/complications , Polyomavirus/isolement et purification , Polyomavirus/génétique , Papillomaviridae/génétique , Papillomaviridae/isolement et purification , Études cas-témoins , Co-infection/virologie , Co-infection/épidémiologie , Sujet âgé , Adulte , Infections à virus oncogènes/virologie , Infections à virus oncogènes/épidémiologie , Infections à virus oncogènes/complications , Génotype
10.
Clin Lab ; 70(6)2024 Jun 01.
Article de Anglais | MEDLINE | ID: mdl-38868876

RÉSUMÉ

BACKGROUND: For women, cervical cancer is the most prevalent cancer and the most common cause of cancer-related deaths worldwide. Human papillomavirus (HPV) is causatively linked to over 90% of cervical cancer cases. Our retrospective study explored the clinical and laboratory data of outpatients with HPV infection to analyze the prevalence and genotype distribution of 3,793 outpatients in the Hangzhou area by using HPV genotype tests. It could provide value for an effective prevention and treatment of HPV infection. METHODS: In total, 3,793 female outpatients were randomly selected from January 2022 to December 2023. Exfoliated cervical cells were collected using a cytobrush and HPV genotype screening was conducted for testing. Data of all outpatients were collected from the hospital's electronic medical records, and SPSS 26.0 software was used to perform the statistical analysis. RESULTS: Out of 3,793 outpatients, 953 were detected as positive, and the positive rate was 25.13%. The age of the outpatients ranged from 15 - 97, with an average age of 39.91. All outpatients were divided into six age groups. Among the six age groups, the HPV positive rates were, with ascending age, 43.90%, 33.27%, 21.49%, 16.99%, 27.30%, and 25.48%, and the highest positive rate was observed in those aged  20 with a rate of 43.90%. There were significant differences in the positive rates among different age groups (p < 0.05). There were more outpatients with a single infection than with multiple infection (p < 0.05). The positive rate of single infection was the highest in the 31 - 40 and 41 - 50 age groups (74.32% for both) and the positive rate of multiple infection was the highest in the  20 age group (66.67%). Among 24 genotypes, HPV 52, 58, and 51 were the most commonly detected. All three were high-risk genotypes, and HPV 52 was the most dominant in all age groups. As distribution according to quarter, more HPV infection occurred in the fourth quarter, which had a significant difference (p < 0.05). And in the first quarter, the number of HPV positive infections was the lowest. CONCLUSIONS: Prevalence and genotype distribution of HPV in the Hangzhou area were different from those of other regions. More single infection, and more multiple infection occurring in low age and in the fourth quarter were the characteristics of HPV infection in the Hangzhou area. It was suggested that vaccine containing HPV 52 might be a better choice for this region.


Sujet(s)
Génotype , Papillomaviridae , Infections à papillomavirus , Humains , Femelle , Chine/épidémiologie , Infections à papillomavirus/épidémiologie , Infections à papillomavirus/virologie , Infections à papillomavirus/diagnostic , Adulte d'âge moyen , Adulte , Prévalence , Études rétrospectives , Jeune adulte , Papillomaviridae/génétique , Papillomaviridae/classification , Sujet âgé , Adolescent , Sujet âgé de 80 ans ou plus , Tumeurs du col de l'utérus/virologie , Tumeurs du col de l'utérus/épidémiologie
11.
CMAJ ; 196(21): E716-E723, 2024 Jun 02.
Article de Anglais | MEDLINE | ID: mdl-38830680

RÉSUMÉ

BACKGROUND: To eliminate cervical cancer in Canada by 2040, defined as an annual age-standardized incidence rate (ASIR) lower than 4.0 per 100 000 women, the Canadian Partnership Against Cancer (CPAC) identified 3 priorities for action: increasing human papillomavirus (HPV) vaccine coverage, implementing HPV-based screening and increasing screening participation, and improving follow-up after abnormal screen results. Our objective was to explore the impact of these priorities on the projected time to elimination of cervical cancer in British Columbia. METHODS: We used OncoSim-Cervical, a microsimulation model led and supported by CPAC and developed by Statistics Canada that simulates HPV transmission and the natural history of cervical cancer for the Canadian population. We updated model parameters to reflect BC's historical participation rates and program design. We simulated the transition to HPV-based screening and developed scenarios to explore the additional impact of achieving 90% vaccination coverage, 95% screening recruitment, 90% ontime screening, and 95% follow-up compliance. We projected cervical cancer incidence, ASIR, and year of elimination for the population of BC for 2023-2050. RESULTS: HPV-based screening at current vaccination, participation, and follow-up rates can eliminate cervical cancer by 2034. Increasing on-time screening and follow-up compliance could achieve this target by 2031. Increasing vaccination coverage has a small impact over this time horizon. INTERPRETATION: With the implementation of HPV-based screening, cervical cancer can be eliminated in BC before 2040. Efforts to increase screening participation and follow-up through this transition could potentially accelerate this timeline, but the transition from cytology- to HPV-based screening is fundamental to achieving this goal.


Sujet(s)
Dépistage précoce du cancer , Infections à papillomavirus , Vaccins contre les papillomavirus , Tumeurs du col de l'utérus , Humains , Tumeurs du col de l'utérus/prévention et contrôle , Tumeurs du col de l'utérus/épidémiologie , Tumeurs du col de l'utérus/diagnostic , Colombie-Britannique/épidémiologie , Femelle , Vaccins contre les papillomavirus/administration et posologie , Infections à papillomavirus/prévention et contrôle , Infections à papillomavirus/épidémiologie , Infections à papillomavirus/diagnostic , Incidence , Adulte , Dépistage précoce du cancer/statistiques et données numériques , Adulte d'âge moyen , Dépistage de masse , Jeune adulte , Sujet âgé , Éradication de maladie
12.
J Med Virol ; 96(6): e29747, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38895783

RÉSUMÉ

This study aimed to provide comprehensive clinical screening data for anal intraepithelial neoplasia (AIN). This study included 312 patients who underwent high-resolution anoscopy (HRA) examinations between January 1, 2020 and April 15, 2024. Clinical data, including demographic information, clinical history, cytology/high-risk human papilloma virus (hrHPV) results, and HRA records, were analyzed. The median age of all patients was 42 years (interquartile range: 33-52 years). Approximately 26.3% reported a history of VIN2/3+, 13.5% had a history of VaIN2/3+, 29.8% had a history of CIN2/3+, 44.6% had persistent cervical HPV16 infection, and 12.5% had immune suppression. Among the 312 patients, 14.4% were diagnosed with AIN2/3, 25.0% with AIN1 and 60.6% were normal. Anal cytological abnormalities were found in 41.3% of all patients, with a significantly higher rate in AIN2/3 patients than in ≤AIN1, 71.1% versus 36.3%, p < 0.001. The hrHPV positivity rate was 89.7%, with HPV16 being the most prevalent. The complete agreement rate for HRA impressions was 79.5%. Multi-variable analysis revealed immune suppression (odds ratio [OR]: 3.47, 95% confidence interval [CI]: 1.42-8.5) and VIN2/3+ (OR: 2.82, 95% CI: 1.27-6.28) were independent risk factors for AIN2/3. Abnormal cytology results (OR: 3.3, 95% CI: 1.52-7.17) and anal HPV16 infection (OR: 3.2, 95% CI: 1.26-8.12) demonstrated similar ORs for AIN2/3. Early screening for AIN2/3+ is crucial in Chinese women with lower genital tract precancerous and cancerous lesions, particularly in those with VIN2/3+ and immune suppression.


Sujet(s)
Tumeurs de l'anus , Épithélioma in situ , Dépistage précoce du cancer , Infections à papillomavirus , Humains , Femelle , Adulte d'âge moyen , Adulte , Chine/épidémiologie , Tumeurs de l'anus/virologie , Tumeurs de l'anus/diagnostic , Tumeurs de l'anus/épidémiologie , Infections à papillomavirus/diagnostic , Infections à papillomavirus/virologie , Infections à papillomavirus/épidémiologie , Dépistage précoce du cancer/méthodes , Épithélioma in situ/épidémiologie , Épithélioma in situ/virologie , Épithélioma in situ/diagnostic , Facteurs de risque , Papillomavirus humain de type 16/isolement et purification
13.
Virol J ; 21(1): 140, 2024 Jun 18.
Article de Anglais | MEDLINE | ID: mdl-38890675

RÉSUMÉ

BACKGROUND: The persistent infection of high-risk Human papillomavirus(HPV) is considered the main cause of cervical intraepithelial neoplasia and cervical cancer. But various cervical lesions caused by HPV infection can be properly prevented by timely vaccination. However, the distribution of HPV genotypes varies geographically. METHODS: Retrospective analysis of high-risk HPV prevalence of 16,150 women from 2020 to 2022 in xianning of China. HPV genotyping was performed using a PCR-RDB Kit that can detect 18 high-risk HPV genotypes recommended by China's National Medical Products Administration. The prevalence of 18 high-risk HPV genotypes and their relationship with cervical lesions as well as vaccine efficacy were analyzed. RESULTS: A total of 2431 women were confirmed to have different types of high-risk HPV infections. The overall positive rate reached 15.05%(2431/16,150). The most prevalent high-risk HPV genotypes were HPV52, 16, 58, 53, and 51. The prevalence of high-risk HPV reached peak at age ≤ 20(20.95%) and age ≥ 61(20.56%). The most prevalent high-risk HPV genotypes were HPV16, 58, 18, 33 and 52 in cervical cancer cases, HPV16, 52, 58, 33 and 18 in CIN2/3 cases, and HPV52, 58, 16, 53 and 18 in CIN1 cases, respectively. CONCLUSION: HPV16, 58 and 18 are the most dangerous and carcinogenic genotypes in xianning, China. Conducting epidemiological investigations on high-risk HPV has significant clinical value in guiding HPV vaccination work.


Sujet(s)
Génotype , Papillomaviridae , Infections à papillomavirus , Tumeurs du col de l'utérus , Humains , Femelle , Chine/épidémiologie , Infections à papillomavirus/épidémiologie , Infections à papillomavirus/virologie , Prévalence , Adulte , Adulte d'âge moyen , Jeune adulte , Études rétrospectives , Papillomaviridae/génétique , Papillomaviridae/classification , Papillomaviridae/isolement et purification , Tumeurs du col de l'utérus/virologie , Tumeurs du col de l'utérus/épidémiologie , Adolescent , Sujet âgé , Dysplasie du col utérin/virologie , Dysplasie du col utérin/épidémiologie , Vaccins contre les papillomavirus/administration et posologie , Virus des Papillomavirus humains
14.
Virol J ; 21(1): 129, 2024 Jun 05.
Article de Anglais | MEDLINE | ID: mdl-38840267

RÉSUMÉ

BACKGROUND: Global human activities were significantly impacted by the emergence of the coronavirus disease 2019 (COVID-19) pandemic caused by the 2019 novel coronavirus. This study aimed to investigate the prevalence and genotype distribution of HPV infection in Central Fujian Province during the pandemic. METHODS: Cervical samples were collected from 21,612 outpatients and 12,664 females who underwent physical examinations and HPV screening at the People's Hospital of Fujian Province in Fuzhou from April 2020 to April 2023. HPV detection and genotyping were conducted using PCR hybridization. RESULTS: The overall HPV infection rate was 16.1% during the COVID-19 pandemic, with the outpatient group exhibiting a greater infection rate (19.0%) than did the healthy group (12.3%). The top five high-risk HPV (HR-HPV) genotypes in both groups were HPV52, HPV53, HPV58, HPV16, and HPV51. Additionally, HPV81 and HPV43 were the two most common low-risk HPV (LR-HPV) genotypes in the patient group, while HPV81 and HPV42 were the two most common LR-HPV genotypes in the healthy group. The highest prevalence of HPV infection was observed in individuals aged ≤ 24 years (28.4%, 95% CI 25.9-30.9), followed by those aged ≥ 55 years (23.6%, 95% CI 21.6-24.7) and other age groups. The prevalence decreased from 23.0% (95% CI 22.4-23.7) in 2018-2019 to 13.8% (95% CI 12.0-15.5) in 2023. CONCLUSION: This study provides valuable insights into the prevalence and genotypes of HPV infection in the female population of Central Fujian Province from 2020 to 2023. The findings indicate that the prevalence of HPV infection in Central Fujian Province remains relatively low compared to the national average. Furthermore, the prevalence of HPV decreased during the COVID-19 pandemic; however, as the pandemic waned, there was potential for an increase in HPV infection rates. Therefore, it is crucial to strengthen HPV screening and vaccination strategies to prevent the potential spread of HPV.


Sujet(s)
COVID-19 , Génotype , Papillomaviridae , Infections à papillomavirus , Humains , Femelle , Infections à papillomavirus/épidémiologie , Infections à papillomavirus/virologie , Chine/épidémiologie , Adulte , Prévalence , COVID-19/épidémiologie , COVID-19/virologie , Adulte d'âge moyen , Jeune adulte , Papillomaviridae/génétique , Papillomaviridae/classification , Papillomaviridae/isolement et purification , SARS-CoV-2/génétique , SARS-CoV-2/isolement et purification , SARS-CoV-2/classification , Adolescent , Sujet âgé , Col de l'utérus/virologie , Virus des Papillomavirus humains
15.
Cancer Med ; 13(11): e7316, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38828559

RÉSUMÉ

OBJECTIVE: To assess the clinical values of extended human papillomavirus (HPV) genotyping in triage of high-risk HPV-positive women, focusing on the trade-off between cervical precancer detections and colposcopy referrals. METHODS: A bivariate random-effects model was used to estimate the diagnostic accuracy of primary HPV screening with following triage strategies to detect cervical precancers: (i) partial genotyping for HPV16/18 combined with cytological testing at atypical squamous cells of undetermined significance threshold (used as the comparator), (ii) genotyping for HPV16/18/58/52, (iii) genotyping for HPV16/18/58/52/33, (iv) genotyping for HPV16/18/58/33/31, (v) genotyping for HPV16/18/58/52/33/31, and (vi) genotyping for HPV16/18/58/52/33/31/39/51. Internal risk benchmarks for clinical management were used to evaluate the risk stratification of each triage strategy. RESULTS: A total of 16,982 women (mean age 46.1 years, range 17-69) were included in this analysis. For CIN3+ detection, triage with HPV16/18/58/33/31 genotyping achieved lower positivity (6.85% vs. 7.35%, p = 0.001), while maintaining similar sensitivity (91.35% vs. 96.42%, p = 0.32) and specificity (94.09% vs. 93.67%, p = 0.56) compared with the comparator strategy. Similar patterns were observed for CIN2+ detection. Women with a positive HPV16/18/58/33/31 genotyping test had high enough risk for CIN3+ for colposcopy referral, while the risk for women with a negative test was below the 1-year return decision threshold according to internal benchmarks. CONCLUSIONS: Our findings suggested extended HPV genotyping is of potential to be used as a triage technique integrated into HPV-based cervical cancer screening, leading to reduced need for colposcopy referral while maintaining similar disease detection and efficient risk stratification.


Sujet(s)
Dépistage précoce du cancer , Génotype , Infections à papillomavirus , Triage , Tumeurs du col de l'utérus , Humains , Femelle , Tumeurs du col de l'utérus/virologie , Tumeurs du col de l'utérus/diagnostic , Tumeurs du col de l'utérus/épidémiologie , Dépistage précoce du cancer/méthodes , Adulte , Infections à papillomavirus/virologie , Infections à papillomavirus/diagnostic , Infections à papillomavirus/épidémiologie , Adulte d'âge moyen , Triage/méthodes , Chine/épidémiologie , Adolescent , Jeune adulte , Colposcopie , Papillomaviridae/génétique , Papillomaviridae/isolement et purification , Dysplasie du col utérin/virologie , Dysplasie du col utérin/diagnostic , Dysplasie du col utérin/épidémiologie , Sujet âgé , Papillomavirus humain de type 18/génétique , Papillomavirus humain de type 18/isolement et purification , Sensibilité et spécificité , Virus des Papillomavirus humains
16.
BMC Public Health ; 24(1): 1485, 2024 Jun 03.
Article de Anglais | MEDLINE | ID: mdl-38831431

RÉSUMÉ

BACKGROUND: The prevalence of, and risk factors for, genital Human Papillomavirus (HPV) infections within the young adult population are well-established; the same is not known for oral HPV. This observational study aimed to determine oral HPV prevalence and abundance within a UK young adult population, and examine if sexual practices and established risk factors of oropharyngeal squamous cell carcinomas (OPSCCs) (such as smoking and alcohol consumption) influenced HPV prevalence. METHODS: Convenience sampling was used to recruit a small sample of 452 UK-based young adults studying at a higher education (HE) institution to the study; the study was not powered. A highly sensitive real-time PCR HPV screening method was developed for the detection of multiple HPV subtypes from oral swabs. HPV-positive samples were subsequently screened by qPCR for viral subtypes HPV-6, HPV-11, HPV-16, HPV-18. Results were analysed by univariate and multivariate methods and stratified for gender, with lifestyle behaviour data collected via questionnaire. Socio-economic status was not captured within the questionnaire. RESULTS: We found a high oral HPV prevalence of 22.79%, with a dominance of high-risk viral type HPV-16 (prevalence 19.12%; abundance average 1.08 × 105 copies/million cells) detected within healthy young adults. Frequent smoking (p = .05), masturbation (p = .029), and engagement in multiple sexual activities (p = .057), were found to be associated with oral HPV prevalence, and HPV-16 prevalence, whilst behaviours traditionally associated with genital HPV were not. CONCLUSIONS: Our results strengthen the link between sexual practices and oral HPV transmission. We suggest that young adults should be considered high-risk for the contraction of oral HPV, although acknowledge that this sample of HE students may not be representative of the wider population. We show that high-risk HPV-16 is prevalent in the healthy population, as well as dominating within OPSCC; this study is one of the first to determine the dominance of oral HPV-16 prevalence and abundance within this population, presenting a clear need for greater awareness of oral HPV infections, and the risk factors for HPV-positive OPSCC within young adults.


Sujet(s)
Infections à papillomavirus , Comportement sexuel , Humains , Infections à papillomavirus/épidémiologie , Mâle , Femelle , Facteurs de risque , Prévalence , Jeune adulte , Royaume-Uni/épidémiologie , Comportement sexuel/statistiques et données numériques , Adulte , Adolescent , Tumeurs de l'oropharynx/épidémiologie , Tumeurs de l'oropharynx/virologie , Papillomaviridae/isolement et purification , Papillomaviridae/génétique , Réaction de polymérisation en chaine en temps réel , Virus des Papillomavirus humains
17.
BMC Womens Health ; 24(1): 322, 2024 Jun 04.
Article de Anglais | MEDLINE | ID: mdl-38834999

RÉSUMÉ

BACKGROUND: Cervical cancer is one of the leading causes of death in women worldwide. The majority of the cases are found in developing countries. The increasing risk of cervical cancer prevalence and growing danger of death from cervical cancer and the high occurrence of human papillomavirus (HPV) infection in women who are HIV positive give us the ground to study the prevalence and associated risk factors. OBJECTIVE: The study aims to assess the prevalence of cervical cancer screening and associated risk factors among HIV-positive women attending the Adult ART clinic at the University of Gondar Hospital. METHODS: An institution-based cross-sectional study was conducted from March to August 2021, on adult HIV-positive women attending the Adult ART clinic at Gondar University Referral Hospital by phone calling patients per week for six months to complete a total of 2744 HIV-positive patients who were not screened for cervical cancer before. The data were collected using an interviewer-administered questionnaire. Bivariate and multivariable logistic regression analyses were used to determine the presence and the degree of association between dependent and independent variables. In the multivariable logistic analysis, a P-value of < 0.05 and odds ratio with a 95% confidence interval were considered to determine independent predictors for the prevalence of premalignant or malignant cervical lesions among HIV-positive patients. RESULT: This study assessed 915 HIV Positive women who were screened for cervical cancer via visual inspection with acetic acid (VIA) as the primary screening tool and found that 24.48% had positive VIA results. Those with VIA-positive cases pathology examination showed 72.4% had abnormal pathology reports (CIN 1/2/3-51.25%, 17.23% cancer & 3.9% CIS), strengthening the finding in many studies that suggest HIV-positive women have a high rate of premalignant lesions.


Sujet(s)
Infections à VIH , États précancéreux , Tumeurs du col de l'utérus , Humains , Femelle , Éthiopie/épidémiologie , Études transversales , Adulte , Tumeurs du col de l'utérus/épidémiologie , Prévalence , Infections à VIH/épidémiologie , Infections à VIH/complications , Facteurs de risque , Adulte d'âge moyen , États précancéreux/épidémiologie , Dépistage précoce du cancer , Jeune adulte , Infections à papillomavirus/épidémiologie , Infections à papillomavirus/complications , Hôpitaux universitaires , Orientation vers un spécialiste/statistiques et données numériques
19.
Sci Rep ; 14(1): 14619, 2024 06 25.
Article de Anglais | MEDLINE | ID: mdl-38918416

RÉSUMÉ

High-risk human papillomavirus (HR-HPV) is the primary carcinogen in uterine cervical carcinoma. While genotype-specific carcinogenic risks have been extensively studied in Western populations, data from Korean are sparse. This study evaluates the malignant potential of the three most prevalent HR-HPVs in Korea: HPV16, HPV52, and HPV58. We analyzed 230 patients who underwent cervical conization and had been tested for HPV within a year prior to the procedure, excluding those with multiple infections. This analysis was confined to patients with single HPV infections and assessed outcomes of CIN3+, which includes carcinoma in situ (CIN3) and invasive carcinoma. The incidence of invasive cervical cancer was 6.7% for HPV16, 1.7% for HPV52, and 2.0% for HPV58; however, these differences were not statistically significant (p = 0.187). The rate of CIN3+ for HPV16, HPV52, and HPV58 were 70.6%, 51.7%, and 58.8%, respectively. Despite the small sample size, which may limit the robustness of statistical analysis, the data suggest a higher observed risk with HPV16. These findings highlight the need for vigilant clinical management tailored to specific HPV genotypes and support the implementation of a nine-valent vaccine in Korea. Physicians should be aware of these genotype-specific risks when treating patients.


Sujet(s)
Infections à papillomavirus , Tumeurs du col de l'utérus , Humains , Femelle , République de Corée/épidémiologie , Tumeurs du col de l'utérus/virologie , Tumeurs du col de l'utérus/anatomopathologie , Infections à papillomavirus/virologie , Infections à papillomavirus/épidémiologie , Adulte , Adulte d'âge moyen , Papillomavirus humain de type 16/génétique , Dysplasie du col utérin/virologie , Dysplasie du col utérin/anatomopathologie , Dysplasie du col utérin/épidémiologie , Col de l'utérus/virologie , Col de l'utérus/anatomopathologie , Génotype , Études de cohortes , Sujet âgé , Papillomaviridae/génétique , Incidence
20.
Viruses ; 16(6)2024 Jun 02.
Article de Anglais | MEDLINE | ID: mdl-38932194

RÉSUMÉ

The menace of human papillomavirus (HPV) infections among low- and middle-income countries with no access to a free HPV vaccine is a public health concern. HPV is one of the most common sexually transmitted infections (STIs) in Nigeria, while the most known types of HPV genotypes being transmitted are the high-risk HPV-16 and 18 genotypes. In this study, we explored the predictors of self-reported HPV infections and HPV genital warts infection among a population of students, non-academic staff, and academic staff of Ibrahim Badamasi Babangida (IBB) University located in Lapai, Nigeria. We also assessed their knowledge about HPV infections and genotypes, and sexual behaviors. An online cross-sectional study was conducted by setting up a structured questionnaire on Google Forms and it was distributed to the university community via Facebook and other social media platforms of the university. The form captured questions on HPV infection, and knowledge about HPV infection and genotypes, as well as the sexual health of the participants. All variables were described using frequencies and percentage distribution; chi-squared test statistics were used to explore the association between HPV infection (medical records of HPV infection) and the participants' profile, and a logistic regression analysis was performed to examine the factors associated with HPV genital warts infection among the population. This study reveals those participants between the ages of 26-40 years (81.3%) and those currently not in a sexually active relationship-single/divorced (26.4%)-who have self-reported having the HPV-16 and -18 genotypes. Moreover, participants between 26-40 years of age (OR: 0.45, 95%CI: 0.22-0.89) reported themselves to be carriers of HPV genital warts. Therefore, this study reveals the factors associated with HPV infection and genital warts peculiar to IBB university students and staff. Hence, we suggest the need for HPV awareness programs and free HPV vaccine availability at IBB university.


Sujet(s)
Condylomes acuminés , Infections à papillomavirus , Autorapport , Étudiants , Humains , Études transversales , Mâle , Femelle , Condylomes acuminés/épidémiologie , Condylomes acuminés/virologie , Nigeria/épidémiologie , Universités , Adulte , Jeune adulte , Infections à papillomavirus/épidémiologie , Infections à papillomavirus/virologie , Connaissances, attitudes et pratiques en santé , Adolescent , Enquêtes et questionnaires , Comportement sexuel/statistiques et données numériques , Génotype , Facteurs de risque , Papillomaviridae/génétique , Papillomaviridae/classification
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...